Key Takeaways
- Revenue up 16% YoY, U.S. leads: Consolidated revenue grew 16.3% YoY, driven by the U.S. segment surging 37% YoY, more than double the company average.
- Gross margin resets to a sustainable 56%: Gross margin expanded 279 bps YoY to 56.2%, a level management calls sustainable after an unsustainably high 59% in Q2, with the reset driven by product mix.
- EBITDA margin compressed by Teva ramp-up: EBITDA margin fell 234 bps to 20.4% as the acquired Teva facility added employee costs and freight costs rose; both headwinds are expected to ease from Q4 onward.
- Teva facility is the central growth bet: The plant hit its first revenue objective of ~INR 30 crores and is still at only ~20% utilization, leaving a long runway toward the INR 800+ crores revenue potential management continues to target.
- What to watch next quarter: Whether freight and employee cost drags actually recede as guided, the pace of Teva’s ramp-up toward a INR 50 crores monthly run rate, and any tariff-related policy shifts that could reset the competitive landscape.
Teva Facility Ramp-Up
- Phased execution underway: The facility has achieved its first revenue milestone of ~INR 30 crores and is progressing through a three-phase plan: first reach the desired operational level, second increase capacity, third secure regulatory variations to utilize that capacity. Steps cannot be skipped.
- Utilization is still low, which is the opportunity: Teva is running at ~20% capacity utilization, while the company’s other plants operate at ~70% with a maximum of ~85%. The wide gap gives a long growth runway as the plant scales.
- 80% of the employment investment is already done: A small percentage of capex remains to hit the next milestone, but the bulk of the headcount build is complete. The remaining employee cost drag should normalize as revenue grows over the next 1–2 quarters.
- Gestation is structural, not a delay: Management explained that in pharma manufacturing, you invest today and see returns later. Once people are on board, there is a ~6-month gestation before optimization and operating leverage materialize.
Mark Saldanha: "you have to get your team ready, you have to have your headcount, you have to have highly qualified people. You have to invest, you have to do the training. And so, you have a gestation of 6 months out there before you actually see optimization or operating leverage happening once they come on board."
Margin Dynamics
- Gross margin expanded YoY, reset QoQ: Gross margin reached 56.2%, up 279 bps YoY on better product mix and lower raw material prices. The sequential decline from Q2’s 59% was expected and reflects a return to a sustainable level after an unusually strong quarter.
- EBITDA margin fell on two temporary drags: EBITDA margin declined 234 bps to 20.4%, driven by employee additions at the Teva facility and higher freight costs. Both are expected to ease: freight cost impact should be visible in Q4, and employee cost drag should fade over the next 1–2 quarters as revenue grows.
- Raw material costs are stable: Raw material prices have softened over time and are now quite stable, with no expected increase. This removes a key source of margin volatility.
- Peak margin recovery has no timeline: When asked about returning to peak margins of 25% EBITDA and 18% PAT, management declined to commit to a timeline, saying only that operating leverage as sales grow will help improve margins.
Revenue Growth & Geographic Mix
- U.S. is the standout engine: The U.S. segment grew 37% YoY, more than double the consolidated growth rate, and remains the primary growth driver.
- U.K. improved, with a doubling ambition: The U.K. showed improvement during the quarter despite a warm winter that softened seasonal demand. Management is bullish and has a growth plan to double U.K. revenue, supported by a robust product pipeline awaiting approvals plus new filings.
- Australia, New Zealand and Rest of World were soft: ANZ was impacted by seasonality, while Rest of World continued to face geopolitical turmoil.
- Revenue target is moving up: Management no longer talks only of the INR 3,000 crores milestone; the team is already working toward INR 4,000 crores, with present capacity sufficient to get closer to that level. Beyond INR 4,000 crores, new capacity infrastructure will eventually be needed.
Mark Saldanha: "we no longer talk of INR 3,000 crores. We are already working towards the INR 4,000 crores mark, the business model and the strategy."
Tariffs & Geopolitical Risk
- Tariff pass-through is the baseline assumption: If tariffs are applied uniformly and no country has a price advantage, costs will rise and those costs will have to be passed down the chain.
- India has an edge if no tariffs materialize: If Indian products remain tariff-free, India holds a competitive advantage. If tariffs are imposed, the playing field levels for all manufacturers.
- The U.S. plant imports material from Europe and India: Any tariff scenario would create cost implications that, absent a price advantage, would need to be passed through to customers.
- No tariffs on the horizon, but uncertainty is the norm: Management noted that tariffs are not currently on the horizon, but political conditions can change rapidly. The company operates with a “hope for the best” posture while acknowledging daily geopolitical uncertainty.
Mark Saldanha: "if it is uniformly, if there is no advantage per se... the cost will go up and that cost will have to be passed down."
Capital Allocation & M&A
- Two early-stage M&A dialogues are live: Management is in dialogue with two companies, but both are at a very initial stage, far from due diligence or a definitive agreement.
- Risk-mitigation defines the M&A philosophy: The company has historically avoided big-ticket deals, not out of aversion but to mitigate the risk of devaluation on acquired assets. Cash reserves are preserved for capital-intensive opportunities.
- No plans for a QIP or preferential raise: Management stated explicitly that there are no plans for equity capital raises.
- Promoter stake increase is not a near-term priority: When asked whether the promoter plans to increase the ~43.8% stake, management deflected, saying it had not given it much thought and would explore it at a different time. Sandra is free to buy from the market, but there is no strategic buying underway.
Mark Saldanha: "Our history will say that we've never gone into some big-ticket deals. We are not averse to it, but we try to avoid any risk or you could say we do a risk mitigation to see that there is no devaluation on what we acquire."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Freight cost drag to end | Freight cost impact visible in Q4; no longer a drag on EBITDA | From Q4 FY25 onward |
| Employee cost drag to normalize | Employee cost from Teva facility becomes no drag on EBITDA as revenue grows | Next 1–2 quarters |
| Teva next revenue milestone | Achieve INR 50 crores monthly run rate, then target INR 80 crores | No date; gated on hitting INR 50 crores first |
| Revenue target | INR 3,000 crores maintained; internally working toward INR 4,000 crores | INR 3,000 crores targeted; INR 4,000 crores is the next milestone |
| U.K. revenue ambition | Double U.K. revenue | No timeline; dependent on product approvals and pipeline |
| Teva revenue potential | INR 800+ crores from the acquired facility | No date; long-term target |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Operating revenue | ₹682 cr, +16.3% YoY |
| U.S. & North America revenue | ₹353 cr, +37.1% YoY |
| U.K. & EU formulation revenue | ₹258 cr, +2.6% YoY |
| Australia & New Zealand revenue | ₹47.2 cr, -2.8% YoY |
| Gross margin | 56.2%, expanded 279 bps YoY from 53.5% |
| EBITDA | ₹138.8 cr, +4.3% YoY |
| EBITDA margin | 20.4%, contracted 234 bps YoY |
| Profit after tax | ₹105.1 cr, +26.6% YoY, all-time high quarterly PAT |
| EPS | ₹2.3 |
| R&D spend | ₹11.8 cr, 1.7% of consolidated revenue |
| Cash balance | ₹669 cr, debt-free as of 31 Dec 2024 |
| Teva facility monthly run rate | ~₹30 cr, annualized ~₹360 cr; next milestone ₹50 cr then ₹80 cr |
| Teva facility capacity utilization | ~20% |
| Rest of plants capacity utilization | ~70%, maximum possible ~85% |
| Freight costs | ~₹40 cr for the quarter |